Joan Clark

Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up.

S. Perrotta, M. Cappellini, A. Piga, 2011, Blood.

Advantages of every-3-week dosing of erythropoietic agents to manage chemotherapy-induced anemia.

A. Schergen, Joan Clark, 2006, Oncology.

Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload

E. Vichinsky, M. Cappellini, R. Galanello, 2009, British journal of haematology.

Efficacy and safety of deferasirox (Exjade®) in patients with β-thalassemia major treated for up to 5 years

S. Perrotta, M. Cappellini, A. Piga, 2009 .